Marc Rybstein in Brooklyn, New York

Medical School: State University Of New York At Stony Brook, School Of Medicine
Graduation Year: 2006
The Primary Medical Specialty for Marc Rybstein is listed as: Cardiovascular Disease (cardiology)
Approximate Years of Experience: 18
PAC (PECOS ID)#: 4082768775
NPI #: 1538393822
NPI Created On: 05/14/2009
NPI Last Updated Listed as: 01/19/2018
Primary Taxonomy Code: 207RC0000X
License Number:
253288
Listed Gender: Male

Forms of insurance accepted by include, but are not limited to:

• Humana
• Medicare

They are listed as accepting new patients.

Languages spoken by staff include: English.

Services and Procedures include:

1. Insertion of needle into vein for collection of blood sample
2. Nuclear medicine study of vessels of heart using drugs or exercise multiple studies
3. Routine ekg using at least 12 leads including interpretation and report
4. Exercise or drug-induced heart and blood vessel stress test with ekg monitoring, physician supervision, interpretation, and report
5. Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function
6. Ultrasound scanning of blood flow (outside the brain) on both sides of head and neck
7. Ultrasound study of arteries of both arms and legs
8. Ultrasound study of arteries and arterial grafts of both legs
9. Ultrasound scan of veins of both arms or legs including assessment of compression and functional maneuvers
10. Ultrasound scan of abdominal, pelvic, and/or scrotal arterial inflow and venous outflow
11. Ultrasound scan of vena cava or groin graft or vessel blood flow
12. New patient office or other outpatient visit, typically 30 minutes
13. Established patient office or other outpatient visit, typically 15 minutes
14. Established patient office or other outpatient, visit typically 25 minutes
15. Technetium tc-99m sestamibi, diagnostic, per study dose
16. Electrocardiogram, routine ecg with 12 leads; performed as a screening for the initial preventive physical examination with interpretation and report
17. Injection, regadenoson, 0.1 mg